Live Market Updates
Latest Financial News
News Feed
1 articles
Personalized
Live Market Updates
Latest Financial News
positive
6 days agoCellatrix Secures $30 Million Series B to Advance Rare Disease Gene Therapies
Bangalore-based biotech startup Cellatrix raised $30 million in Series B funding led by international venture investors, with participation from strategic healthcare funds. The capital will support development of next-generation gene therapies targeting rare genetic disorders and expand preclinical research facilities. Management said proceeds will accelerate IND filings and enable manufacturing scale-up under global regulatory compliance. Analysts highlighted India’s growing biotech funding ecosystem as a catalyst for translational medicine. The company aims to enter clinical trials for its lead candidate within 18 months.
positive
6 days agoCellatrix Secures $30 Million Series B to Advance Rare Disease Gene Therapies
Bangalore-based biotech startup Cellatrix raised $30 million in Series B funding led by international venture investors, with participation from strategic healthcare funds. The capital will support development of next-generation gene therapies targeting rare genetic disorders and expand preclinical research facilities. Management said proceeds will accelerate IND filings and enable manufacturing scale-up under global regulatory compliance. Analysts highlighted India’s growing biotech funding ecosystem as a catalyst for translational medicine. The company aims to enter clinical trials for its lead candidate within 18 months.
positive
Cellatrix Secures $30 Million Series B to Advance Rare Disease Gene Therapies
6 days ago
1 min read
82 words
Cellatrix raised $30 million to develop gene therapies for rare disorders, expanding India’s biotech innovation and advancing clinical readiness timelines.
Bangalore-based biotech startup Cellatrix raised $30 million in Series B funding led by international venture investors, with participation from strategic healthcare funds. The capital will support development of next-generation gene therapies targeting rare genetic disorders and expand preclinical research facilities. Management said proceeds will accelerate IND filings and enable manufacturing scale-up under global regulatory compliance. Analysts highlighted India’s growing biotech funding ecosystem as a catalyst for translational medicine. The company aims to enter clinical trials for its lead candidate within 18 months.
Bangalore-based biotech startup Cellatrix raised $30 million in Series B funding led by international venture investors, with participation from strategic healthcare funds. The capital will support development of next-generation gene therapies targeting rare genetic disorders and expand preclinical research facilities. Management said proceeds will accelerate IND filings and enable manufacturing scale-up under global regulatory compliance. Analysts highlighted India’s growing biotech funding ecosystem as a catalyst for translational medicine. The company aims to enter clinical trials for its lead candidate within 18 months.
Companies:
Cellatrix
Tags:
startups
biotech
startups
biotech
Cellatrix
funding
gene therapy
Oct 25, 2025 • 17:20 IST